» Articles » PMID: 15684297

Long-term Clearance from Small Airways in Patients with Cystic Fibrosis

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2005 Feb 3
PMID 15684297
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Impaired mucociliary clearance is a hallmark of cystic fibrosis (CF). Early morphological changes first appear in the small airways. Lung clearance was investigated in 11 young CF adults with mild-to-moderate lung disease using a method depositing particles mainly in the small airways. Radiolabelled Teflon particles (6 microm) were inhaled with an extremely slow inhalation flow, 0.05 L x s(-1). Lung retention was measured immediately following inhalations and, on four occasions up to 21 days. The results were compared with data from healthy subjects. The lung retention at 24 h in % of deposition was 67% (95% confidence interval 58-76) in the CF patients, compared to 48% (42-53) in the healthy subjects. Clearance on days 1-7 was larger in the CF patients, 22% (15-29) compared to the healthy subjects, 14% (12-16). No difference was observed between the CF patients and the healthy subjects in the slow clearance phase at day 7 to day 21, representing small airway clearance. Impaired mucociliary clearance in CF patients results in increased 24-h retention and a prolonged rapid clearance phase. The results of the study do not support the current authors' hypothesis that clearance from small airways is slower in cystic fibrosis patients compared to healthy subjects. Furthermore, the data suggest that mucociliary transport is not the dominant clearance mechanism in small airways.

Citing Articles

Polyelectrolyte Complex Dry Powder Formulations of Tobramycin with Hyaluronic Acid and Sodium Hyaluronate for Inhalation Therapy in Cystic Fibrosis-Associated Infections.

de Lafuente Y, Quarta E, Magi M, Apas A, Pagani J, Palena M Antibiotics (Basel). 2025; 14(2).

PMID: 40001413 PMC: 11851662. DOI: 10.3390/antibiotics14020169.


Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.

Soto M, Lewis M, Leal J, Pan Y, Mohanty R, Veyssi A Mol Ther Nucleic Acids. 2024; 35(4):102375.

PMID: 39640013 PMC: 11617931. DOI: 10.1016/j.omtn.2024.102375.


Controlled inhalation improves central and peripheral deposition in cystic fibrosis patients with moderate lung disease.

Bourke C, Devadason S, Ditcham W, Depiazzi J, Everard M J Paediatr Child Health. 2022; 58(6):1066-1068.

PMID: 35174574 PMC: 9303168. DOI: 10.1111/jpc.15909.


Novel outcome measures for clinical trials in cystic fibrosis.

Tiddens H, Puderbach M, Venegas J, Ratjen F, Donaldson S, Davis S Pediatr Pulmonol. 2015; 50(3):302-315.

PMID: 25641878 PMC: 4365726. DOI: 10.1002/ppul.23146.


An advanced stochastic model for mucociliary particle clearance in cystic fibrosis lungs.

Sturm R J Thorac Dis. 2012; 4(1):48-57.

PMID: 22295167 PMC: 3256542. DOI: 10.3978/j.issn.2072-1439.2011.09.09.